Clinical trial
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone…
NCT00399477 · Teva Neuroscience, Inc., Industry · Completed
Key facts
| NCT number | NCT00399477 |
|---|---|
| Title | A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease |
| Official title | Open-label, Multicenter, Effectiveness and Safety Study of Once Daily AZILECT® as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinson's Disease (PD) |
| Lead sponsor | Teva Neuroscience, Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | rasagiline mesylate, Rasagiline mesylate plus Mirapex, Rasagiline mesylate with Levodopa, Rasagiline mesylate with Requip |
| Enrollment | 200 |
| Start date | Oct 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Nov 14, 2006 |
| Last update posted | Apr 12, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: